Navigation Links
Flu Viruses Gaining Resistance, Study Confirms
Date:12/7/2010

TUESDAY, Dec. 7 (HealthDay News) -- Certain influenza virus strains are developing increasing drug resistance and greater ability to spread, a new study warns.

American and Canadian researchers confirmed that resistance to the two approved classes of antiviral drugs can occur in several ways and said this dual resistance has been on the rise over the past three years.

The team analyzed 28 seasonal H1N1 influenza viruses that were present in five countries from 2008 to 2010 and were resistant to both M2 blockers (adamantanes) and neuraminidase inhibitors (NAIs), including oseltamivir and zanamivir.

The researchers found that additional antiviral resistance can rapidly develop in a previously single-resistant influenza virus through mutation, drug response, or gene exchange with another virus.

The study also found that the proportion of tested viruses with dual resistance increased from 00.6 percent in 2007-08 to 1.5 percent in 2008-09 and 28 percent in 2009-10.

The findings are published online Dec. 7 in advance of print publication Jan. 1 in the Journal of Infectious Diseases.

"Because only two classes of antiviral agents are approved, the detection of viruses with resistance to drugs in both classes is concerning," study author Dr. Larisa Gubareva, of the U.S. Centers for Disease Control and Prevention, said in a journal news release.

"If circulation of these viruses with dual resistance becomes more widespread among any of the predominant circulating influenza A viruses, treatment options will be extremely limited," she added. "New antiviral agents and strategies for antiviral therapy are likely to be necessary in the future."

Another study in the same issue of the journal examined an outbreak of oseltamivir-resistant pandemic H1N1 influenza in a hematology unit in a British hospital. The researchers concluded "that oseltamivir may not be the frontline drug of choice in hematology patients, and zanamivir may prove to be more beneficial."

In an editorial accompanying the two studies, experts said increased monitoring and creative prevention and treatment choices will be needed as unpredictable and antiviral-resistant influenza viruses continue to appear.

With only two classes of antiviral drugs approved for use in most countries, future research should focus on the effectiveness of zanamivir and combination antiviral therapy and the development of new types of antiviral drugs, wrote Dr. Frederick G. Hayden, of the University of Virginia School of Medicine, and Dr. Menno D. de Jong, of the University of Amsterdam in the Netherlands.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about influenza.

-- Robert Preidt

SOURCE: Journal of Infectious Diseases, news release, Dec. 7, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Potential new treatment for deadly nipah and hendra viruses identified by Weill Cornell researchers
2. Targeting hit-and-run cancer viruses
3. Researchers find function of proteins that can enhance the progression of viruses and cancer cells
4. To attack H1N1, other flu viruses, gold nanorods deliver potent payload
5. Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses
6. Oncolytic viruses mediating anti-tumor immunity in human cancer patients
7. Mild-mannered metabolic helper rushes to fight invading viruses, researchers report
8. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
9. UBC graduate student finds a start/stop switch for retroviruses
10. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
11. Gaining Weight Raises Risk of Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Flu Viruses Gaining Resistance, Study Confirms
(Date:4/28/2016)... ... ... The Aging in Motion Coalition (AIM) has announced the Centers ... it recognition for separate reporting and data collection. The code, M62.84, will be available ... as a combination of low muscle mass and weakness in older adults that causes ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... by a health insurance co-operative bankruptcy to receive their prescription medications through ... over 1,500 FDA-approved prescription medications from over 180 American pharmaceutical companies for ...
(Date:4/28/2016)... ... April 28, 2016 , ... Today Nimblify, Inc. ... Calendar Exchange , is officially open to all sponsors in the industry. The ... to download into their clinical trial management system (CTMS), which is the site’s ...
(Date:4/28/2016)... ... April 28, 2016 , ... On ... Officer at the Steadman Philippon Research Institute in Vail, Colorado, attended the ... awareness about the debilitating and costly musculoskeletal disorders that are affecting millions of ...
(Date:4/28/2016)... Valley, California (PRWEB) , ... ... ... Inc. (AGNITY) a leading global provider of intelligent business communication applications and ... and go-live of its Number Portability solution at Bestel’s Communications Network. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 2016 Dr. ... und Stephen Schmidt werden ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen für ... dass neue Führungskräfte zum Team Sicherheit und ... vielfältige Erfahrungen mitbringen.  Dies wird die Geschäftseinheit ...
(Date:4/28/2016)... -- Dr. Vivek Ahuja , ... Ste phen Schmidt Join ... cloud-based software solutions for life sciences, today announced key new leaders ... of insight to a growing business.  This will bolster the company,s ... Phillips joined ArisGlobal in the position of Vice President - ...
(Date:4/28/2016)... Florida , April 28, 2016 ... the development of innovative peptide and gene-based immunotherapeutics and vaccines ... it will be presenting at the 3rd Annual Growth ... - 5 th , 2016 at Caesars Palace in Las Vegas, ... 8.00 am on Wednesday, May 4 th by Dr. ...
Breaking Medicine Technology: